NCT07340320招募中2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus
Corxel Pharmaceuticals51 个研究点 分布在 2 个国家目标入组 240 人开始时间: 2026年2月6日最近更新:
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 240
- 试验地点
- 51
- 主要终点
- Change in Glycosylated hemoglobin, Type A1C (HbA1c) from baseline
研究概览
简要总结
This study is testing whether a new medication called CX11 works and is safe for participants with type 2 diabetes who have not reached good blood sugar control while taking a steady dose of metformin, with or without a steady dose of an SGLT2 inhibitor, for at least 90 days.
The study is being done at multiple medical centers. Participants are assigned by chance (randomized) to different groups, and neither the participants nor the study staff know which group they're in (double-blind). The groups are compared side by side (parallel), and some participants will receive inactive pills (placebo) to help measure the true effect of the study drug.
After screening, participants will be randomly placed into one of six groups, with equal chances of being in any group. Each group will receive a different dose of CX11 or a placebo. Treatment will last 24 weeks. After that, all participants will have a 2-week follow-up period to check on safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants who meet all of the following criteria will be eligible to participate in this study:
- •Adults aged 18 to
- •Diagnosis of type 2 diabetes for at least 6 months.
- •HbA1c between 7.0% and 10.5%.
- •Body mass index (BMI) between 23 and 50 kg/m².
- •Body weight stable for the past 3 months before joining.
- •Stable dose of metformin (≥1000 mg/day), with or without SGLT2i, for ≥3 months.
- •Women of childbearing potential (WOCBP): highly effective contraception ≥6 months prior to screening, throughout study, and 90 days post-last dose; negative pregnancy test within 24 hrs of first dose; no intent to donate sperm/ova
- •Agrees to avoid grapefruit/grapefruit products
排除标准
- •Participants who meet any of the following criteria will be excluded from this study:
- •Anticipated initiation or change in concomitant medications (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids).
- •Type 1 diabetes or a history of diabetic ketoacidosis.
- •Use of any GLP-1 receptor agonist within the past 6 months, or any prior exposure to CX
- •Use of insulin to control blood sugar within the past 12 months.
- •More than one episode of severe low blood sugar, with awareness of hypoglycemia symptoms.
- •Cardiovascular or cerebrovascular conditions within the past 6 months:
- •Heart attack, coronary angioplasty, or bypass surgery (diagnostic angiography allowed).
- •Valvular heart disease or prior heart valve repair surgery.
- •Unstable angina.
- •Transient ischemic attack (TIA) or stroke.
- •Decompensated heart failure (NYHA Class III or IV).
- •ECG abnormalities indicating significant safety risk, such as supraventricular tachycardia, torsades de pointes, second- or third-degree AV block, myocardial infarction, QTcF > 450 ms in males or > 470 ms in females, PR interval > 220 ms.
- •Poorly controlled hypertension at screening: systolic ≥ 180 mmHg or diastolic ≥ 100 mmHg.
- •Pancreatic or gallbladder conditions:
- •Acute or chronic pancreatitis.
- •Symptomatic gallbladder disease (previous cholecystectomy is allowed).
- •Pancreatic injury or risk factors that increase pancreatitis risk.
- •Thyroid conditions:
- •Poorly controlled abnormal thyroid function on a stable dose before screening.
- •Clinically significant abnormal thyroid test results at screening.
- •Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) type 2A or 2B.
- •Cancer history:
- •Malignancy within the past 5 years, regardless of recurrence or metastasis. Exceptions: localized basal cell skin cancer, low-risk prostate cancer, cervical carcinoma in situ, or high-grade prostatic intraepithelial neoplasia.
- •Gastrointestinal conditions or treatments that may affect drug absorption:
- •Abnormal gastric emptying (e.g., gastric outlet obstruction).
- •Severe chronic gastrointestinal disease, including active ulcer within 6 months.
- •Crohn's disease, ulcerative colitis, or other inflammatory bowel diseases.
- •Prior gastrointestinal surgery (except polypectomy and appendectomy).
- •Long-term use of drugs that directly affect gastrointestinal motility (e.g., mosapride, cisapride).
- •Liver disease:
- •Active liver disease other than nonalcoholic fatty liver.
- •Chronic active hepatitis B or C.
- •Primary biliary cirrhosis.
- •Eye disease:
- •Uncontrolled or potentially unstable diabetic retinopathy or maculopathy.
- •Abnormal lab results at screening:
- •eGFR < 60 mL/min/1.73 m² (CKD-EPI).
- •ALT or AST > 2.5 × upper limit of normal (ULN).
- •Total bilirubin > 1.5 × ULN (except known Gilbert's syndrome).
- •Serum amylase or lipase > 1.5 × ULN.
- •Fasting triglycerides > 5.7 mmol/L.
- •TSH > 1.5 × ULN or < 1.0 × LLN.
- •Calcitonin ≥ 20 ng/L.
- •Hemoglobin < 110 g/L (male) or < 100 g/L (female).
研究组 & 干预措施
200 mg group
Experimental
干预措施: CX11 (Drug)
Placebo group
Placebo Comparator
干预措施: Placebo (Other)
40 mg group
Experimental
干预措施: CX11 (Drug)
80 mg group
Experimental
干预措施: CX11 (Drug)
160 mg group
Experimental
干预措施: CX11 (Drug)
120 mg group
Experimental
干预措施: CX11 (Drug)
结局指标
主要结局
Change in Glycosylated hemoglobin, Type A1C (HbA1c) from baseline
时间窗: At Week 24
次要结局
- Proportion of participants achieving HbA1c < 7.0%(At Week 24)
- Proportion of participants achieving HbA1c ≤ 6.5%(At Week 24)
- Change from baseline in Time in Range (TIR) measured by Continuous Glucose Monitoring (CGM)(To Week 24)
- Change from baseline in fasting plasma glucose (FPG)(To Week 24)
- Change in body weight from baseline(To Week 24)
- Percent change in body weight from baseline(To Week 24)
- Proportion of participants achieving body weight loss ≥ 5%(At Week 24)
- Proportion of participants achieving body weight loss ≥ 10%(At Week 24)
- Change in Systolic Blood Pressure (SBP) from baseline(To Week 24)
- Change in Diastolic Blood Pressure (DBP) from baseline(To Week 24)
- Number of Level 2 hypoglycemic episodes (glucose <54 mg/dL)(To Week 24)
- Number of severe hypoglycemic episodes(To Week 24)
- Number of treatment-emergent adverse events (TEAEs)(Study duration, approximately 26 weeks)
- Number of AEs of special interest (AESIs)(Study duration, approximately 26 weeks)
- Plasma drug concentrations at each specified sampling time point(At Weeks 2, 4, 6, 8, 12, 16, 22 and 24)
- Mean plasma drug concentration at each specified sampling time point(At Weeks 2, 4, 6, 8, 12, 16, 22 and 24)
研究者
研究点 (51)
Loading locations...
相似试验
招募中
2 期
A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic ArthritisNCT07315061InventisBio Co., Ltd222
尚未招募
3 期
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）NCT07274137MindRank AI Ltd738
招募中
2 期
EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)NCT07287670Mediar Therapeutics85
招募中
2 期
Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)Ulcerative ColitisNCT07265570InSilico Medicine Hong Kong Limited80
终止
2 期
A Clinical Trial of TQH2929 Injection in Patients With Acute Flare-up of Generalized Pustular PsoriasisGeneralized Pustular PsoriasisNCT07314060Chia Tai Tianqing Pharmaceutical Group Co., Ltd.36